Machine learning sharpened six-year diabetes risk—but the simple questionnaire still held up
In an Iranian cohort of 8,859 adults, random forest discrimination exceeded the established FINDRISC score. The result is internally validated prediction, not proof that screening or treatment outcomes improve.
The short version
- What happened
- The analysis included 8,859 adults with complete six-year follow-up; 525 developed type 2 diabetes, an incidence of 6.0%.
- Who it affects
- A more accurate risk ranking could help target prevention, but this study does not establish who should be tested or whether acting on the score improves health.
- What remains unproven
- Internal rather than external validation
Keep in mind
Internal rather than external validation
One Iranian population cohort
No intervention or patient-outcome comparison
AUC alone does not establish clinical net benefit
Source analysis · 1 linked source. Primary analysed source date: 24 October 2026.
Read the full report · 3 min The evidence, methods, implications and limitations
The machine-learning gain was measurable, not transformative
Researchers followed 8,859 Iranian adults who did not have diabetes at baseline and had complete information six years later. During follow-up, 525 participants developed type 2 diabetes. The team compared the established Finnish Diabetes Risk Score, or FINDRISC, with logistic regression and several machine-learning approaches using demographic, lifestyle and clinical predictors.
FINDRISC produced an area under the receiver-operating-characteristic curve of 0.76 (95% confidence interval 0.74–0.79). Random forest performed best at 0.81 (0.79–0.83). A FINDRISC threshold above 12 identified 73.0% of later cases while correctly excluding 68.4% of non-cases; lowering the threshold above 11 raised sensitivity to 78.9% but reduced specificity to 61.1%.[1]
External validation and clinical consequences come next
For patients and primary-care teams, a short questionnaire remains attractive because it is inexpensive and interpretable. A five-point AUC difference may help rank risk, but it does not say how many complications are prevented or whether extra testing creates avoidable anxiety and cost. The machine-learning models were validated within the same cohort, so performance may fall in other populations, health systems or time periods.
The assessment would change with prospective external validation that fixes the predictors and threshold in advance, compares screening strategies, reports calibration and decision benefit, and follows real prevention and diagnosis outcomes. The authors reported no specific funding and no competing interests.[1]
The distinction that matters
Prediction is not the same as better care
The study compared ranking performance, not a screening programme or treatment pathway.
FINDRISC
Score routine risk factors
AUC 0.76
Random forest
Learn nonlinear patterns
AUC 0.81
Clinical impact
Not tested
No prevention or patient outcome